Abstract
After the US Supreme Court eliminated the federal constitutional right to abortion in 2022, several high-profile legal fights have centered on US Food and Drug Administration (FDA) oversight of mifepristone. Mifepristone (200 mg) is approved, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days' gestation. Legal battles over Mifepristone have included a lawsuit challenging the FDA’s initial approval of the drug and the sufficiency of FDA-required restrictions on the drug, as well as lawsuits arguing, to the contrary, that FDA-required restrictions are unnecessary and must be eliminated.
DOI
DOI:10.1001/jama.2025.19752
External Links
https://jamanetwork.com/journals/jama/fullarticle/2840574
Repository Citation
Greer Donley, Lewis Grossman & Patricia J. Zettler,
State Mifepristone Regulation Following GenBioPro v Raynes,
334
JAMA
(2025).
Available at:
https://digitalcommons.wcl.american.edu/facsch_lawrev/2344